Oxeia Biopharma in the News
New Treatment for Concussion with Dr. Bansal on Recovery Now with Kim Justus
Dr. Vishal Bansal, MD. FACS is a physician with a dream: he wants to develop the first FDA-approved therapies that treat not only the immediate symptoms of concussion, but the underlying damage. This podcast with head injury survivor Kim Justus delves into the science behind Oxeia’s hormone Ghrelin, OXE103.
The Hill: Mild Traumatic Brain Injuries Can Lead to a Lifetime of Health Issues for Soldiers
Concussions are a serious health problem in the military. In January, 2020, 109 US servicemen in Iraq suffered traumatic brain injury from Iranian airstrikes. But this is just the latest occurrence; in the last 9 years over 413,000 troops were diagnosed with TBI.
In this article, Oxeia co-founder and chief scientific officer, Vishal Bansal, calls on Congress, the Pentagon, and the medical establishment to increase their commitment to finding an effective treatment to protect our proud members of the military.
News Release: Oxeia preparing for Phase 2 human clinical studies
Oxeia Biopharmaceuticals' CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference in London in December. Oxeia is preparing for the launch of Phase 2 human clinical studies for its therapeutic drug to treat concussions.
CNBC: Betting on software and against concussions
49ers star Richard Sherman is betting on software and against concussions as he dives into start-ups. One of the startups is Oxeia Biopharmaceuticals, which is developing a concussion drug that would treat the immediate symptoms and the underlying damage.
CBS Sports Radio: Richard Sherman stops by the Tiki and Tierney Show
San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.
News Release: Dr. Michael Wyand appointed as CEO
Oxeia Biopharmaceuticals Inc. announces the appointment of Michael Wyand, DVM, PhD as Chief Executive Officer. Dr. Wyand will also join Oxeia’s Board of Directors.
FiercePharma: Richard Sherman Joins Oxeia Advisory Board
NFL All-Pro Richard Sherman joins Oxeia board as it readies phase 2 concussion drug research
Richard Sherman, NFL All-Pro, Joins Advisory Board
Oxeia Biopharmaceuticals Inc. announces Richard Sherman, cornerback of the Seattle Seahawk’s (National Football League), as a member of its Advisory Board.
News Release: Oxeia Biopharmaceuticals Announces Clinical Advancement of Concussion Treatment
Oxeia Biopharmaceuticals Inc., announces its acquisition of the license to SUN11031, synthetic human ghrelin, from Kinemed Inc. Oxeia will develop SUN11031 as OXE103 to treat concussions and other acute neurotrauma.
News Release: Christopher Nowinski Joins Oxeia
Christopher Nowinski, co-founder and CEO of the Concussion Legacy Foundation, has joined the company’s Advisory Board.
News Release: Oxeia Biopharma Advancing Treatment of Concussions
Oxeia Biopharmaceuticals, Inc. Advancing Development of OXE103 for the Treatment of Concussions
“I became an advisor to Oxeia to contribute to an action that could change the face of how concussions are treated. Wouldn’t it be great if football players, hockey players and boxers, among others, could play their sport without the constant worry of repercussions from getting walloped in the head? Oxeia’s progress toward the delivery of a treatment for concussions fills me with great excitement about the future of sports.”
Richard Sherman
Cornerback for the San Francisco 49ers and
Advisory Board Member, Oxeia Biopharmaceuticals